O le a le uiga o le “manino”?
E le tauaveina e le manu le suiga. O le a le tupu ai le ma'i ma o le a lē tuʻuina atu.
The Cardiomyopathy With Juvenile Mortality (CJM) DNA test in dogs is essential for early detection of this hereditary heart condition. CJM causes severe heart muscle disease leading to sudden death in young dogs, making genetic screening crucial for breeders and pet owners. By identifying carriers and affected dogs, the CJM DNA test helps prevent the spread of this fatal disorder within breeding lines. Early diagnosis through this test allows for better management and care of at-risk dogs. Reliable and accurate, the CJM DNA test supports responsible breeding practices and promotes healthier canine populations. Ensure your dog’s health and future by opting for the Cardiomyopathy With Juvenile Mortality DNA test today. Protect your pet with advanced genetic testing designed to save lives.
The DNA test for Cardiomyopathy With Juvenile Mortality (CJM) in dogs helps identify carriers of this genetic condition. CJM is a serious heart disease that can cause sudden death in young dogs. Early detection through testing allows breeders to make informed decisions and reduce the risk of passing the mutation to offspring. This test is especially important for breeds known to be affected by CJM. Responsible breeding based on DNA results promotes healthier future generations of dogs.
O lenei su'ega DNA e aofia ai e amata mai i le matou pusa Basic — ma o se vaega foi o pusa Basic, Standard, Advanced, Complete.
Va'ai DNA Su'ega Packs →Cardiomyopathy With Juvenile Mortality (CJM) is a serious and often fatal heart condition that primarily affects young dogs. It is characterized by the degeneration of heart muscle, leading to impaired heart function and, in severe cases, sudden cardiac death. CJM typically presents in dogs under the age of two, making early detection and intervention crucial for improving outcomes.
The underlying cause of CJM involves genetic mutations that disrupt the normal structure and function of cardiac muscle cells. As the disease progresses, the heart becomes progressively weaker, resulting in decreased cardiac output and potential rhythm disturbances. These changes can lead to symptoms such as lethargy, weakness, and exercise intolerance, which may rapidly escalate to life-threatening conditions.
Dogs affected by CJM may exhibit a range of clinical signs, including coughing, difficulty breathing, and fainting episodes. Due to the rapid progression of the disease, it is essential for pet owners to seek veterinary attention promptly if they notice any concerning symptoms. Diagnosis typically involves a combination of physical examinations, echocardiography, and electrocardiograms to assess heart function and identify abnormalities.
While there is currently no cure for CJM, management strategies aim to improve the quality of life and prolong survival for affected dogs. Treatment may include medications to support heart function, reduce fluid buildup, and manage arrhythmias. Additionally, lifestyle modifications, such as restricted exercise and regular veterinary check-ups, play an important role in managing the condition effectively.
Genetic testing for CJM is a valuable tool for identifying at-risk dogs and guiding breeding decisions. By understanding the genetic predisposition to this condition, breeders can make informed choices to reduce the incidence of CJM in future generations. Furthermore, early identification of affected individuals allows for timely intervention and better management of the disease.
Cardiomyopathy With Juvenile Mortality (CJM) represents a significant health concern in young dogs, emphasizing the importance of awareness, early detection, and genetic testing. By recognizing the signs of this condition and seeking appropriate veterinary care, pet owners can help ensure their dog's health and well-being. Ongoing research and advancements in genetic testing continue to provide hope for better management and prevention strategies for CJM.
E le tauaveina e le manu le suiga. O le a le tupu ai le ma'i ma o le a lē tuʻuina atu.
Leai. E masani ona soifua maloloina le manu ae e mafai ona tuʻuina atu le suiga i lona fanau.
E lua kopi suia. Fa'ailoga fa'afoma'i e fa'amoemoe e fa'atatau i le faama'i. E le tatau ona fafaga.
O nisi faʻamaʻi e fesoʻotaʻi feusuaʻiga, o lea e eseese ai o latou faʻaaliga e faʻatatau i le itupa a manu.
This DNA test detects the mutation associated with Cardiomyopathy With Juvenile Mortality (CJM) in order to identify clear, carrier, or at-risk animals.
O le su'ega DNA e fesoasoani i le au faifa'ato'aga e fuafua ni faigauo saogalemu ma fa'aitiitia ai le lamatiaga o le tu'uina atu o le suiga i fanau.
Ole fa'asologa ole tofi na lipotia mo lenei su'ega ole Autosomal Recessive.
This test analyses the mutation YARS2 c.1054G>A.
E le faapea. O le fa'auigaina e fa'alagolago i le fa'asologa o tofi ma le fa'atupuina o le genotype.
Gurtner Corinne, Hug Petra, Kleiter Miriam, Köhler Kernt, Dietschi Elisabeth, Jagannathan Vidhya, Leeb Tosso. YARS2 Missense Variant in Belgian Shepherd Dogs with Cardiomyopathy and Juvenile Mortality. Genes (Basel). 2020 Mar 14;11(3):313. doi: 10.3390/genes11030313.
O lau fa'alilolilo, lau filifiliga
Matou te fa'aogaina kuki taua e fa'atautaia ai le upega tafa'ilagi. O kuki e filifili ai (e pei o kamupani o lo'o fa'apipi'i) e fa'aletonu ona o le fa'aletonu ma e na'o le avanoa pe a e malie. E mafai ona e suia lau filifiliga i soʻo se taimi e faʻaaoga ai le ki "Kuki".
Manaomia mo vaega autu ma le saogalemu. E mafai i taimi uma.
Fa'aleleia foliga e pei o le fa'apolopolo o mea e mana'o i ai po'o mea e le fa'asalalauga.
Fesoasoani ia matou malamalama i le fa'aogaina o nofoaga. Ua le atoatoa ona o le faaletonu.
Fa'asalalauga/su'esu'e i luga ole laiga (o nisi ata vitio/fa'afanua fa'apipi'i). Ua le atoatoa ona o le faaletonu.